Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort); most pediatric asthma patients receive more than one agent to treat their condition. Despite the availability of multiple, well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including salmeterol / fluticasone generics and novel biological drugs (e.g., Regeneron / Sanofi’s Dupixent, GSK’s Nucala). These events have added more treatment options and fueled competition in this market.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric asthma patients?
  • What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?
  •  How have newer biological therapies, such as AstraZeneca’s Fasenra, been integrated into the treatment algorithm, and what are their sources of business?
  •  What percentage of pediatric asthma patients receive drug therapy within 365 days of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of pediatric asthma patients are treated with monotherapy versus combination therapy?
  • What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


  • United States

Real world data

  •  Longitudinal patient-level claims data analysis

Key drugs covered:

  • Advair, Symbicort, Dulera, Breo, Fasenra, Nucala, Xolair, Ventolin, ProAir, montelukast sodium, Flovent, Spiriva

Key analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Asthma - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pediatric Asthma (US)
    • Treatment Algorithm: Claims Data Analysis Pediatric Asthma US April 2020

Author(s): Elena Kozhemyakina, PhD

Elena Kozhemyakina, PhD, is a Senior Business Insight Analyst at Decision Resources, Inc., specializing in pharmaceutical market analysis of the immune system disorders with expertise in Systemic Lupus Erythematosus, asthma, Crohn’s disease and ulcerative colitis.

Prior to joining Decision Resources, Dr. Kozhemyakina completed a postdoctoral fellowship at Harvard Medical School, where she investigated molecular mechanisms involved in limb patterning, cartilage formation and pathogenesis of osteoarthritis. She published multiple peer-reviewed papers focused on molecular signalling of developmental disorders.

Related Reports

Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

The asthma market in the EU5 is highly competitive. Ma...

View Details

Asthma - Landscape & Forecast - Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details

Asthma - Unmet Need - Detailed, Expanded Analysis (Severe Asthma)

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the entry of

View Details